| Santarus Announces Development Program for New ZEGERID Prescription Product
|
(Santarus)
|
28-May-2008 |
| Positive Clinical Data with Santarus' ZEGERID Capsules in Controlling 24-Hour Gastric Acidity Presented in DDW Abstract
|
(Santarus)
|
19-May-2008 |
| ABILIFY(R) (aripiprazole) Receives Expanded Indications for Maintenance Treatment in Both Pediatric Patients (Aged 10-17) With Manic and Mixed Episodes of Bipolar I Disorder and Adolescents (Aged 13-17) With Schizophrenia
|
(Bristol-Myers Squibb)
|
08-May-2008 |
| U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Add-On Treatment to Lithium or Valproate in the Acute Treatment of Adults With Manic and Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features
|
(Bristol-Myers Squibb)
|
08-May-2008 |
| Abilify® (aripiprazole) Receives Expanded Indications for Maintenance Treatment in Both Pediatric Patients (aged 10-17) With Manic and Mixed Episodes of Bipolar I Disorder and Adolescents (aged 13-17) With Schizophrenia
|
(Otsuka Pharmaceutical)
|
08-May-2008 |
| U.S. Food and Drug Administration Approves Abilify® (aripiprazole) for Add-on Treatment to Lithium or Valproate in the Acute Treatment of Adults With Manic and Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features
|
(Otsuka Pharmaceutical)
|
08-May-2008 |
| Bristol-Myers Squibb and Otsuka Receive European Marketing Authorisation for Abilify® in the Treatment and Prevention of Moderate to Severe Manic Episodes in Bipolar I Disorder
|
(Otsuka Pharmaceutical)
|
08-Apr-2008 |
| Abraxis Bioscience Announces Filing of Marketing Application in Japan for ABRAXANE in the Treatment of Breast Cancer
|
(Abraxis BioScience)
|
17-Mar-2008 |
| U.S. Food and Drug Administration Approves ABILIFY® (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated with Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
|
(Bristol-Myers Squibb)
|
29-Feb-2008 |
| U.S. Food and Drug Administration Approves ABILIFY® (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
|
(Otsuka Pharmaceutical)
|
29-Feb-2008 |
| Bristol-Myers Squibb and Otsuka Receive Positive CHMP Opinion for Abilify® (aripiprazole) in Bipolar I Disorder
|
(Otsuka Pharmaceutical)
|
22-Feb-2008 |
| Santarus Announces Positive Clinical Results with ZEGERID Capsules in Controlling Gastric Acidity Over 24 Hours
|
(Santarus)
|
07-Jan-2008 |
| New Drug Application for Tolvaptan, Otsuka’s Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia, Accepted by the U.S. Food and Drug Administration
|
(Otsuka Pharmaceutical)
|
21-Dec-2007 |
| Sativex® Commences US Phase II/III Clinical Trial in Cancer Pain
|
(GW Pharmaceuticals)
|
26-Nov-2007 |
| U.S. Food and Drug Administration Approves ABILIFY® (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
|
(Bristol-Myers Squibb)
|
20-Nov-2007 |
| ABILIFY® (aripiprazole) Supplemental New Drug Application For The Treatment Of Pediatric Patients With Bipolar I Disorder Accepted For Priority Review By The U.S. Food And Drug Administration
|
(Bristol-Myers Squibb)
|
15-Nov-2007 |
| ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration
|
(Otsuka Pharmaceutical)
|
15-Nov-2007 |
| U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients with Schizophrenia
|
(Otsuka Pharmaceutical)
|
06-Nov-2007 |
| Data Reinforce the Value of UFT® as an Important Treatment Option for Patients With Metastatic Colorectal Cancer
|
(Merck KGaA)
|
26-Sep-2007 |
| ECLIPSE Data on Effects of Otsuka’s Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients’ Hemodynamics and Urine Output Featured in Heart Failure Society of America’s Late Breaking Trials
|
(Otsuka Pharmaceutical)
|
19-Sep-2007 |
| ABILIFY® (aripiprazole) Supplemental New Drug Application Receives Priority Review by U.S. Food and Drug Administration for Adjunctive Treatment in Adults with Major Depressive Disorder
|
(Bristol-Myers Squibb)
|
17-Jul-2007 |
| Abilify® (Aripiprazole) Supplemental New Drug Application Receives Priority Review by U.S. Food and Drug Administration for Adjunctive Treatment in Adults With Major Depressive Disorder
|
(Otsuka Pharmaceutical)
|
17-Jul-2007 |
| GW and Otsuka Enter into Global Cannabinoid Research Collaboration
|
(GW Pharmaceuticals)
|
09-Jul-2007 |
